Amyotrophic Lateral Sclerosis: Incorporating Real-World Evidence and the Latest Clinical Data into Managed Care Strategies

A 1.5-hour Accredited On-Demand Virtual Symposium Presented at AMCP Annual 2021

This activity is supported by an educational grant from
Mitsubishi Tanabe Pharma America, Inc.

Faculty Presenters
Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Professor, Department of Neurology
Anschutz Medical Campus
University of Colorado
Aurora, Colorado

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Senior Director, Clinical Analytics
WellDyne
Lakeland, Florida

Medical Writing Support

Brittany Hoffmann-Eubanks, PharmD, MBA
Owner
Banner Medical, LLC
Frankfort, Illinois

Program Description
Patients with amyotrophic lateral sclerosis (ALS) experience progressively worsening physical function. Disruption of upper and lower motor neurons are involved in ALS, with lower motor neurons found in the spinal cord and brain stem and upper motor neurons found in the motor cortex. The time from symptom onset to diagnosis can be up to 1 year, and by the time patients receive a diagnosis, nearly 50% to 70% of motor neurons have been impaired. Pharmacists can promote earlier treatment, which has shown to delay progression in some patients, and can encourage clinicians to increase efforts for early identification with screening tools and treatment guidelines. It is currently recommended that both approved drugs, riluzole and edaravone, be prescribed for all patients with ALS regardless of stage or condition, provided there are no contraindications for their use. Gene-based approaches to disease-modifying drugs are currently under investigation, with promising results in slowing the progression of ALS. Pharmacists are well positioned to assess emerging therapy options and can collaborate with managed care professionals to develop treatment protocols as new data and treatments become available.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

Explore the economic burden of amyotrophic lateral sclerosis (ALS) treatment and management as well as the severe impact on patient quality of life
Examine the most recent real-world and clinical data for currently available and investigational agents for the management of ALS
Apply recent data and scientific advances to drug utilization management strategies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-162-H01-P. The activity is available for CE credit through April 26, 2022.

Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES, and Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, have no relevant financial relationships with commercial interests to disclose.

Medical Writing Support

Brittany Hoffmann-Eubanks, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms